We are live on ! Find out more
NI

Nextech Invest Portfolio holdings

AUM $1.42B
1-Year Est. Return 304.47%
This Fund
S&P 500
This Quarter Est. Return
+18.24%
1 Year Est. Return
+304.47%
3 Year Est. Return
+631.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$712M
AUM Growth
+$118M
Cap. Flow
+$23.6M
Cap. Flow %
3.32%
Top 10 Hldgs %
90.92%
Holding
15
New
2
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$17.9M
2
ZYME icon
Zymeworks
ZYME
+$12.1M
3
MRSN
Mersana Therapeutics
MRSN
+$4.48M

Top Sells

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$9.48M
2
CGEM icon
Cullinan Oncology
CGEM
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$38.6B
$286M 40.09%
6,296,740
– –
TYRA icon
2
Tyra Biosciences
TYRA
$1.84B
$95.4M 13.39%
4,055,861
– –
ORIC icon
3
Oric Pharmaceuticals
ORIC
$1.2B
$54.2M 7.61%
5,285,714
– –
CRGX
4
DELISTED
CARGO Therapeutics
CRGX
$48.8M 6.84%
2,642,502
– –
TNGX icon
5
Tango Therapeutics
TNGX
$4.21B
$42.6M 5.98%
5,533,980
– –
ARVN icon
6
Arvinas
ARVN
$535M
$34.7M 4.87%
1,408,394
– –
RLAY icon
7
Relay Therapeutics
RLAY
$4.01B
$27.2M 3.82%
3,846,409
– –
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$22.8M 3.2%
482,690
+101,644
+27% +$4.48M
CGEM icon
9
Cullinan Oncology
CGEM
$1.04B
$19.1M 2.68%
1,141,145
-80,000
-7% -$1.42M
SLN
10
Silence Therapeutics
SLN
$540M
$17.3M 2.43%
952,400
– –
SPRY icon
11
ARS Pharmaceuticals
SPRY
$574M
$16.1M 2.27%
1,113,029
-797,000
-42% -$9.48M
ALMS
12
Alumis Inc
ALMS
$3.36B
$15.8M 2.21%
+1,476,998
New +$17.9M
CNTX icon
13
Context Therapeutics
CNTX
$54.2M
$14.5M 2.04%
7,419,355
– –
ZYME icon
14
Zymeworks
ZYME
$1.62B
$14M 1.96%
+1,113,946
New +$12.1M
BOLD
15
Boundless Bio
BOLD
$55.7M
$4.26M 0.6%
1,228,069
– –

Similar funds

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return
KCMH
Kontiki Capital Management (HK) Hong Kong $1.43B AUM 9.81% 1-Year Est. Return
APCM
Alaska Permanent Capital Management Anchorage, Alaska $1.43B AUM 13.12% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Nextech Invest's Q3 2024 Portfolio in Review

As of Q3 2024, Nextech Invest held 15 positions worth $712M, up 20% from $594M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Nextech Invest deployed $23.6M of net new capital in Q3 2024, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Alumis Inc: 1,476,998 shares worth $15.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ARS Pharmaceuticals, an estimated $9.48M trimmed.

  • Nextech Invest's largest Q3 2024 buy was Alumis Inc: 1,476,998 shares worth $15.8M.
  • Nextech Invest added most to Mersana Therapeutics in Q3 2024, an estimated $4.48M increase.
  • Nextech Invest's biggest Q3 2024 reduction was ARS Pharmaceuticals, cutting an estimated $9.48M.
  • Nextech Invest's ten largest holdings make up 91% of its $712M portfolio in Q3 2024.
  • Nextech Invest opened 2 new positions and closed 0 in Q3 2024.
  • Nextech Invest's portfolio value rose 20% quarter-over-quarter to $712M.

Based on Nextech Invest's 13F filing for Q3 2024, filed 14 Nov 2024.